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Introduction
“Severe pain” is the most common reason for medicinal
herbal cannabis use, with arthritis and musculoskeletal
pain cited as the most prevalent speciﬁc medical condition
(1,2). Eighty percent of marijuana users in a US pain clinic
report use for myofascial pain, whereas up to one-third of
persons in population studies in the UK and Australia
reported use for treatment of arthritis pain (1–3). Similarly,
“severe arthritis” is the diagnosis for 65% of Canadians
authorized to possess cannabis for medicinal purposes as
of June 2013 (4). Medical marijuana has, however, never
been recommended by any rheumatology group world-
wide for symptom relief in rheumatic conditions. As the
health care professionals best placed to advise on issues of
rheumatic diseases, rheumatologists must have a voice in
the current debate concerning medical marijuana, here-
after identiﬁed as herbal cannabis.
Advocacy for access to cannabinoid treatments has led
to a societal groundswell, with regulatory bodies around
the globe considering the legalization of herbal cannabis
for medicinal use. Currently, herbal cannabis is legalized
for medicinal use in 20 states in the US as well as in the
District of Columbia. Physicians will therefore be caring
for patients who may be self-medicating with herbal can-
nabis or may request medical advice about cannabis. In
order to responsibly advise patients on any medical issue,
and in particular herbal cannabis, it is essential that the
health care professional has a competent knowledge of the
subject based on sound scientiﬁc study. In this review, we
examined the current evidence for dosing and administra-
tion, efﬁcacy, and risks of herbal cannabis in rheumatic
pain management, and thereby addressed practical issues
confronting rheumatologists whose patients request ad-
vice. We conﬁned our comments to herbal cannabis as it
pertains to rheumatic conditions, acknowledging that ev-
idence and information may differ for other conditions.
We did not enter into the debate addressing the legaliza-
tion of recreational herbal cannabis.
Herbal cannabis
Prior to present day pharmacology, healers and patients
sought relief from pain and suffering by using natural
products. The plant Cannabis sativa, commonly known as
marijuana, has been used for pain relief for millennia, with
additional effects on appetite, sleep, and mood, but with
psychoactive properties leading to recreational use (5).
The analgesic effects of herbal cannabis, derived from the
dried leaves and ﬂowers, have been most studied in neu-
ropathic pain conditions.
C sativa contains more than 450 compounds, with at
least 70 classiﬁed as phytocannabinoids, two of which
have particular medical interest (6). The acid precursor
of 9-tetrahydrocannabinol (9-THC), transformed by heat
into THC, has psychoactive and pain-relieving properties.
The second molecule is cannabidiol, with lesser afﬁnity
for the cannabinoid receptors and the potential to coun-
teract the negative effects of THC on memory, mood, and
cognition. Cannabinoid molecules interact with at least
two receptors of the human endocannabinoid system to
induce physiologic effects (7,8).
Herbal cannabis may be ingested or inhaled, with the
latter route preferred by users due to onset of action
within a few minutes. Smoking of cannabis is, however,
not medically recommended due to the potential respira-
tory tract dangers of noxious compounds such as poly-
cyclic aromatic hydrocarbons, tar, and carbon monoxide.
Furthermore, plasma concentrations of THC achieved by
smoking a “joint,” containing between 0.5 and 1.0 gm of
dried substance, are extremely variable, with blood levels
varying between 7 and 100 ng/ml. Finally, blood levels
are inﬂuenced by the plant concentration of THC, variable
THC delivered in the smoke, and characteristics of the
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smoking method (frequency of inhalation, hold time, and
inhalation volume) (9,10). There is also discordance be-
tween the measured THC plasma peak and the maximum
subjective psychoactive effects that occur an hour later,
and can be augmented by opioids. Oral administration
results in a more delayed effect, lower peak plasma levels,
more protracted pharmacologic effects, and less abuse-
related psychoactive effects (11). However, gastrointesti-
nal absorption is more erratic and much of the ingested
cannabinoid is eliminated by ﬁrst-pass metabolism in the
liver (11).
The mean concentration of THC in illicit marijuana
has almost doubled worldwide in the past decade (12).
With THC content of the plant material varying between
1% and 30%, and the bioavailability varying between 2%
and 56%, there is no reasonable method to estimate dosing
of the herbal compound (13). Since acquisition of herbal
cannabis for medical reasons is mostly via the illegal route,
even where medical use is legalized, these higher con-
centrations of THC might lead to increased physical and
psychomotor effects. Therefore, the lack of the most ele-
mentary requirements for responsible drug administration
must call into question any use of herbal cannabis for
rheumatic pain treatment at this time.
Pain management of patients with rheumatic pain
As arthritis pain contributes to poor patient global well-
being, pain relief is an important outcome goal, but un-
fortunately, pain treatments remain suboptimal in most
patients (14). The overriding principle for any pain treat-
ment is to maintain function without sacriﬁcing cognitive
or psychomotor function, a concept clearly different from
pain management for medical conditions predominantly
requiring palliation.
Chronic rheumatic pain remains a challenge, since pain
mechanisms are complex dynamic interactions of mole-
cules and nerve pathways subject to nervous system plas-
ticity. Available drugs generally offer a modest effect only,
and pain co-associates with sleep disturbance and mood
disorders. As treatment success is considered a 30% re-
duction in pain, and because most pain-relieving medica-
tions are associated with considerable side effects, the
compliance with prescribed treatments is often poor. It is
therefore understandable that patients will continue to
seek other remedies to reduce symptoms. Patients with
rheumatic disease commonly use complementary and
alternative medicine, and with increasing advocacy for
legalization of herbal cannabis as a recreational drug, can-
nabis may be perceived as a safe treatment option.
Evidence for herbal cannabis in rheumatic
conditions
To date, there is no formal study examining the efﬁcacy or
adverse effects of herbal cannabis in rheumatic diseases
(15). Since our previous review, there has been only a
single additional study reporting poorer function and psy-
chological health in ﬁbromyalgia patients using cannabi-
noids (16). While there is good evidence for efﬁcacy of
cannabinoids for treating some chronic pain conditions,
such as cancer and neuropathic pain, these pain types
have a different underlying mechanism from the mostly
peripheral/nociceptive pain in rheumatic diseases (17).
Therefore, one cannot extrapolate efﬁcacy to patients with
rheumatic conditions.
Information about the effects of cannabinoids in rheu-
matic diseases is currently derived from anecdotal reports,
two small epidemiologic studies, a single study of the
oromucosal spray of nabiximols, a combination of 9-THC
and cannabidiol, in patients with rheumatoid arthritis,
and two studies of nabilone, a synthetic analog of THC, in
ﬁbromyalgia (1,2,18–20). The two population studies
from the UK andAustralia, with prevalent use formusculo-
skeletal symptoms, raise a number of concerns: diagnosis
and outcome were by patient self-report, patients self-
medicated without knowledge of dosing or concomitant
treatments, and one-third of the users reported recre-
ational use (1,2). Conclusions based on these studies are
therefore questionable. In contrast, when the nabiximol
was examined in a randomized clinical trial of 58 patients
with rheumatoid arthritis over a 5-week period, there
was improvement in pain and quality of sleep (20). The
nabilone studies in ﬁbromyalgia patients showed im-
proved pain in one, and noninferiority to amitriptyline
for the effect on sleep for the other (18,19). However, the
reported effects of these agents, which indeed belong to
the class of cannabinoids, cannot necessarily be applied
to herbal cannabis, which is a different substance, as de-
scribed above.
It therefore follows that critical evaluation of safety is-
sues that pertain to both short-term and long-term effects
of herbal cannabis also have never been formally reported
in persons with classic rheumatic diseases. There is also
no sound information regarding the recommended dosing
of herbal cannabis, other than patient report. Therefore,
the available evidence for efﬁcacy of medical herbal can-
nabis represents the least convincing form of scientiﬁc
evidence.
Evidence for risks
Contrary to public belief, inhaled herbal cannabis is not
innocuous. Risks can be categorized as the immediate
effects on cognition, psychomotor function, cardiovascu-
lar effects, and mood, and the chronic consequences on
mental ability, pulmonary function, potential cancer risk,
and drug dependence. Information on risks of herbal can-
Signiﬁcance & Innovations
● Legitimate use should be reserved only for patients
with pain refractory to standard pharmacologic
and nonpharmacologic therapies.
● Herbal cannabis should not be smoked.
● The risk/beneﬁt proﬁle of herbal cannabis is in-
ferior to all other analgesic classes other than
opioids.
● Persons ages 25 years should be strongly dis-
couraged from any use of herbal cannabis.
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nabis is also mostly derived from reports of recreational
users, who are usually younger and in better health than
those with a chronic disease. Additionally, the interaction
of herbal cannabis with other medications that are being
used therapeutically is mostly unknown.
Acute risks
The acute dose-related effects on cognition and psycho-
motor function are the most well-known immediate con-
sequences of herbal cannabis use, with implications for
patient safety. Following administration of inhaled can-
nabis in varying THC concentrations, regular cannabis
users showed impairment in reaction time, selective at-
tention, short-term memory, and motor control for up to
5 hours following consumption, with increasing effects
for increasing doses (21). Similarly, the memory-impairing
effects of acute cannabis use, possibly speciﬁcally attrib-
utable to THC, should be kept in mind. These acute effects
have implications for medicinal use for two reasons: THC
content in street cannabis is increasing and chronic pain
management requires continued treatment.
Adverse acute effects on psychomotor function are par-
ticularly relevant when subjects drive motorized vehicles.
Arthritis per se is seldom a contraindication to drive,
and driving in the developed world is an important con-
tribution to independence and quality of life. Acute can-
nabis use is increasingly appreciated as an accident risk
for drivers. In a systematic review and meta-analysis of
9 studies, with inclusion of 49,000 participants, acute
cannabis use was associated with at least twice the risk
of serious and fatal motor vehicle collisions (22). Indeed,
cannabis was also the most prevailing illicit drug identi-
ﬁed in 0.5–7.6% of seriously injured drivers from 6 Euro-
pean countries (23). Although alcohol remains the most
common substance identiﬁed in injured drivers, cannabis
was ranked second, with the risk increased when com-
bined with alcohol. Health Canada warns that the ability
to drive or perform activities requiring alertness or coor-
dination may be impaired for up to 24 hours following a
single consumption (24). Therefore, driving with the con-
comitant use of herbal cannabis is both a personal and a
societal safety risk, which may be further compounded in
the presence of other medications. At the very least, med-
ical practitioners must now advise patients that herbal
cannabis may impair motor coordination, particularly
when driving. However, advising patients not to drive is a
recommendation counterintuitive to maintaining normal
function.
A less appreciated effect of acute cannabis is noted for
the cardiovascular system. Tachycardia and hypotension
could compromise cardiovascular status in those with un-
derlying heart disease and be a risk for cardiovascular
events (25). Cannabis increases the risk of myocardial in-
farction 5-fold and reduces the exercise capacity of those
with angina pectoris by half (26,27). Lastly, immediate
psychiatric effects are increasingly associated with acute
cannabis use, including anxiety, agitation, suicidal ide-
ation, and acute psychosis (28).
Chronic risks
The long-term risks of herbal cannabis use in patients with
rheumatic disease are unknown. Risks generic to all per-
sons using herbal cannabis include effects on psychologi-
cal health and association with mental illness, develop-
ment of dependence and addiction, effects on memory,
and cognition and respiratory health (28). Aggravation of
depression- and smoking-associated risks may be particu-
larly important for rheumatology patients. These issues
seem to be particularly problematic in younger individu-
als, where we appreciate that many neuroactive drugs may
have additional or more pronounced side effects (29). For
example, just as suicidality with selective serotonin re-
uptake inhibitors seems more pronounced in individuals
ages25 years, there is a similar age predisposition for the
increased risk of psychosis in young cannabis users.
Although the long-term effect on mood and especially
depression still remains unclear, depression is more prev-
alent in current cannabis users (30). In a US study of
more than 8,000 adults, those with cannabis use in the past
year had 1.4 times higher odds of current depression than
nonusers (30). Aggravation or unmasking of serious psy-
chiatric disease also occurs with herbal cannabis use. Al-
though previously disputed, cannabis is now generally
accepted as an agent with addictive potential, especially in
a context of an adverse psychosocial setting. Over a 3-year
period, the cumulative incidence of cannabis dependence
was 37.2% (95% conﬁdence interval [95% CI] 30.7–43.8%)
for young recreational users (31).
While cigarette smoking–associated risks for arthritis
patients cannot immediately be attributed to the smoking
of herbal cannabis, the potential for these adverse ef-
fects exists. Apart from the consequences of inhalation of
an irritant on respiratory mucosa with development of
chronic respiratory disease, there is increasing evidence
that herbal cannabis may independently increase risk of
lung cancer (32–34). When Swedish military conscripts
ages 18–20 years were tracked over a 40-year period, those
who had smoked cannabis on at least 50 occasions had a
2-fold risk (hazard ratio 2.12, 95% CI 1.08–4.14) of devel-
oping lung cancer, even after adjustments for other risks
for lung cancer (34). Although it is recommended that
herbal cannabis not be smoked, this remains the most
common route of administration for most persons.
Finally, the true motive for use of herbal cannabis, even
in persons with an identiﬁable medical condition, requires
careful scrutiny. Often, persons using marijuana for med-
ical reasons have previously been recreational users, rais-
ing the possibility of misusing a medical diagnosis to
justify use primarily for nonmedical reasons (1,2,35).
Understanding the dilemma for the health care
professional
Responsible medical practice requires a physician to pro-
vide empathetic and judicious patient care without harm.
In light of the current lack of concrete medical evidence for
either the efﬁcacy or risks of herbal cannabis for the man-
agement of rheumatic symptoms, physicians are obligated
to caution patients about the known risks of herbal canna-
bis that have been reported for recreational users. Simply
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acceding to patient demands for a treatment on the basis of
popular advocacy, without comprehensive knowledge of
an agent, does not adhere to the ethical standards of med-
ical practice. It is understandable that this lack of current
scientiﬁc evidence must translate into physician insecu-
rity and even distress when attempting to provide rational
advice to a patient. Furthermore, any recommended ther-
apy requires proof of concept by sound scientiﬁc study
that attests to both efﬁcacy and safety. Therefore, before
physicians can provide medical recommendation or sup-
port for use of herbal cannabis, the minimal standards for
pharmacotherapy must be met. At present, these elemen-
tary criteria are not fulﬁlled. In the absence of knowledge
of effective dosing or true beneﬁts for herbal cannabis for
rheumatic symptoms, the risks extrapolated from study of
persons with recreational use seem to tip the balance
against use. Therefore, we believe that herbal cannabis
should not at this time be allowed exceptional status as a
therapy, different from other modes of therapy.
The question arises, then, whether physicians have any
basis on which to provide responsible advice to patients
beyond the known risk of serious adverse effects. In many
jurisdictions, legislation is forcing physicians to accept
medical responsibility for their patients who may be using
herbal cannabis. For example, in Canada, physicians
will be required to provide a document equivalent to a
prescription stipulating dosing, frequency, and duration of
use (24,36). An additional challenge is presented by the
ambiguous terminology used by the courts whereby legal
access to herbal cannabis is deemed a Charter Right when
a “medical need” has been demonstrated by the patient. If
physicians are to “prescribe” medical cannabis for their
patients, medical ethics and deontology require physician
competence with the prescribed treatment. It is also in-
creasingly recognized that sanctioning use of herbal can-
nabis for therapeutic reasons is currently provided by
small numbers of physicians for the majority of patients
(35). In the state of Colorado, almost half of the recommen-
dations had been made by only 15 physicians. Motives for
this medical behavior should be questioned and raise eth-
ical concerns.
It is therefore not surprising that recent surveys report
that physicians lack conﬁdence in their knowledge of
cannabinoids and in their competence to effectively advise
patients on the use of medicinal cannabinoids (35). In a
survey of family physicians in Colorado, only 19%
thought that physicians should recommend medical mar-
ijuana, with 92% reporting the need for more education
(35). Similarly, two-thirds of Canadian rheumatologists
recently surveyed expressed poor conﬁdence in their
knowledge of cannabinoid medical use, with 70% stating
that there is currently no role for herbal cannabis in the
treatment of rheumatic symptoms (37). Even in the setting
of some reasonable knowledge of cannabinoid molecules
and the endocannabinoid system, the absence of evidence
for clinical use of herbal cannabis in rheumatic conditions
must be discomforting for any health care professional or
rheumatologist intending to provide an herbal cannabis
treatment recommendation. Additional knowledge of
these molecules is required, but knowledge alone will not
ﬁll the void due to absence of clinical study. This evident
mismatch between dictates from regulatory bodies, patient
advocacy, and prudent clinical care is troubling; irrespon-
sible requirements by regulatory authorities might com-
promise patient and society well-being. In light of other
available treatment options for the management of arthritis
pain, lack of sound evidence for effect, and potential for
harm, herbal cannabis cannot be recommended for arthri-
tis pain management at this time.
Conclusion
There is an ever-increasing hiatus between public advo-
cacy for herbal cannabis as a therapeutic agent in rheu-
matic conditions and the medical evidence for efﬁcacy
and side effects. This serious shortfall covers many aspects
of herbal cannabis as a therapeutic agent, including un-
certainty of compound content, unknown dosing, recom-
mendations not to use by inhalation, and the indicators of
harm, both in the acute as well as chronic setting. Taking
all factors into consideration, health care professionals
should currently dissuade rheumatology patients from us-
ing herbal cannabis as a therapy. The evident mismatch
between patients’ needs and good medical practice may
in part be politically driven, with regulatory bodies acced-
ing to public pressure. Rheumatologists should advocate
for further study of individual cannabinoid molecules
whereby dosing can be accurately controlled and efﬁcacy
and safety can be assessed using a standard scientiﬁc
method.
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